| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
FBRX
Forte Biosciences
|
Jul 09, 2026 | BUY |
Strong Buy
-5.9% avg upside
14 analysts
|
$75.00
82.40% Upside
|
· |
|
ABVX
Abivax SA Sponsored ADR
|
Jul 01, 2026 | BUY |
Strong Buy
-3.8% avg upside
15 analysts
|
$175.00
27.53% Upside
|
+5.5% |
|
PRAX
Praxis Precision Medicines
|
Jun 30, 2026 | BUY |
Strong Buy
+67.2% avg upside
24 analysts
|
$800.00
156.21% Upside
|
-2.9% |
|
DBVT
DBV Technologies SA - American
|
Jun 30, 2026 | BUY |
Strong Buy
+50.1% avg upside
15 analysts
|
$51.00
221.14% Upside
|
-3.5% |
|
ZURA
Zura Bio
|
Jun 29, 2026 | BUY |
Strong Buy
+184.7% avg upside
13 analysts
|
$15.00
193.55% Upside
|
-2.5% |
|
ARGX
Argenx Se
|
Jun 24, 2026 | BUY |
Strong Buy
-14.1% avg upside
46 analysts
|
$1135.00
30.38% Upside
|
+2.9% |
|
EYPT
EyePoint Pharmaceuticals
|
Jun 24, 2026 | BUY |
Strong Buy
+132.9% avg upside
19 analysts
|
$68.00
379.63% Upside
|
+2.2% |
|
SION
Sionna Therapeutics, Inc.
|
Jun 23, 2026 | BUY |
Strong Buy
+21.9% avg upside
11 analysts
|
$50.00
15.06% Upside
|
+10.4% |
|
CLYM
Climb Bio
|
Jun 08, 2026 | BUY |
Strong Buy
+36.6% avg upside
18 analysts
|
$35.00
165.70% Upside
|
· |
|
ZBIO
Zenas BioPharma, Inc.
|
Jun 05, 2026 | BUY |
Strong Buy
+48.4% avg upside
11 analysts
|
$55.00
94.97% Upside
|
+55.0% |
|
OCS
Oculis Holding
|
Jun 01, 2026 | BUY |
Strong Buy
+189.9% avg upside
11 analysts
|
$45.00
246.93% Upside
|
-6.1% |
|
ROIV
Roivant Sciences
|
May 26, 2026 | BUY |
Strong Buy
-7.2% avg upside
17 analysts
|
$36.00
4.06% Upside
|
+21.2% |
|
IMVT
Immunovant
|
May 26, 2026 | BUY |
Strong Buy
+0.8% avg upside
24 analysts
|
$62.00
61.16% Upside
|
+21.2% |
|
ALMS
Alumis Inc.
|
May 15, 2026 | BUY |
Strong Buy
+37.3% avg upside
11 analysts
|
$34.00
23.23% Upside
|
+23.8% |
|
CABA
Cabaletta Bio
|
May 15, 2026 | BUY |
Strong Buy
+393.9% avg upside
16 analysts
|
$16.00
479.75% Upside
|
+0.0% |
|
SABS
SAB Biotherapeutics
|
May 13, 2026 | BUY |
Strong Buy
+183.2% avg upside
14 analysts
|
$15.00
294.68% Upside
|
-6.6% |
|
IFRX
InflaRx
|
May 08, 2026 | BUY |
Buy
+347.0% avg upside
11 analysts
|
$14.00
600.00% Upside
|
-7.8% |
|
NMRA
Neumora Therapeutics, Inc.
|
May 07, 2026 | BUY |
Buy
+377.8% avg upside
11 analysts
|
$14.00
788.82% Upside
|
-18.0% |
|
STOK
Stoke Therapeutics
|
May 07, 2026 | BUY |
Strong Buy
+28.6% avg upside
18 analysts
|
$60.00
99.36% Upside
|
-4.3% |
|
AVTX
Avalo Therapeutics
|
May 06, 2026 | BUY |
Strong Buy
+178.8% avg upside
20 analysts
|
$50.00
170.06% Upside
|
-25.0% |
|
DNTH
Dianthus Therapeutics
|
May 06, 2026 | BUY |
Strong Buy
-8.2% avg upside
29 analysts
|
$200.00
106.52% Upside
|
+7.9% |
|
AXSM
Axsome Therapeutics
|
May 04, 2026 | BUY |
Strong Buy
-3.2% avg upside
28 analysts
|
$260.00
14.25% Upside
|
+4.5% |
|
PHAT
Phathom Pharmaceuticals
|
Apr 30, 2026 | BUY |
Strong Buy
+157.1% avg upside
14 analysts
|
$25.00
126.79% Upside
|
-2.5% |
|
REGN
Regeneron
|
Apr 30, 2026 | BUY |
Strong Buy
+16.5% avg upside
58 analysts
|
$995.00
50.73% Upside
|
-5.9% |
|
BIIB
Biogen
|
Apr 29, 2026 | BUY |
Strong Buy
+19.7% avg upside
52 analysts
|
$260.00
23.98% Upside
|
+2.5% |
|
ORKA
Oruka Therapeutics
|
Apr 27, 2026 | BUY |
Strong Buy
+40.4% avg upside
16 analysts
|
$200.00
135.13% Upside
|
+13.6% |
|
IMUX
Immunic
|
Mar 24, 2026 | BUY |
Strong Buy
+157.3% avg upside
21 analysts
|
$70.00
377.58% Upside
|
+10.9% |
|
ACET
Adicet Bio
|
Mar 13, 2026 | BUY |
Strong Buy
+190.8% avg upside
14 analysts
|
$100.00
1041.58% Upside
|
+22.5% |
|
XENE
Xenon
|
Mar 09, 2026 | BUY |
Strong Buy
-6.9% avg upside
28 analysts
|
$90.00
34.59% Upside
|
+1.0% |
|
ANAB
AnaptysBio
|
Mar 04, 2026 | BUY |
Strong Buy
+5.8% avg upside
26 analysts
|
$140.00
103.60% Upside
|
+64.5% |
|
CLDX
Celldex
|
Feb 26, 2026 | BUY |
Strong Buy
+1.6% avg upside
28 analysts
|
$90.00
136.72% Upside
|
+27.6% |
|
MLTX
MoonLake Immunotherapeutics
|
Feb 24, 2026 | BUY |
Buy
+42.9% avg upside
20 analysts
|
$20.00
0.56% Downside
|
+11.9% |
|
TEVA
Teva Pharmaceutical
|
Nov 18, 2025 | HOLD |
Buy
-9.2% avg upside
39 analysts
|
— | +29.5% |
|
NBIX
Neurocrine
|
Oct 28, 2025 | BUY |
Strong Buy
+0.8% avg upside
37 analysts
|
$175.00
0.13% Downside
|
+20.2% |
|
LRMR
Larimar Therapeutics
|
Sep 29, 2025 | BUY |
Strong Buy
+368.9% avg upside
22 analysts
|
$26.00
584.24% Upside
|
+6.8% |
|
ACAD
ACADIA Pharmaceuticals
|
Feb 27, 2025 | HOLD |
Strong Buy
+40.3% avg upside
42 analysts
|
$20.00
21.55% Downside
|
+27.0% |
|
SRZN
Surrozen
|
Jan 03, 2025 | BUY |
Buy
+52.9% avg upside
7 analysts
|
$45.00
101.63% Upside
|
+26.6% |
|
QTTB
Q32 Bio
|
Dec 11, 2024 | HOLD |
Buy
+247.7% avg upside
24 analysts
|
— | -46.6% |
|
SYRE
Spyre Therapeutics
|
Mar 04, 2024 | BUY |
Strong Buy
-15.5% avg upside
23 analysts
|
$50.00
46.72% Downside
|
-47.9% |
|
SEELQ
Seelos Therapeutics
|
Sep 21, 2023 | HOLD |
Buy
+46385614.3% avg upside
10 analysts
|
— | -99.6% |
|
RLMD
Relmada Therapeutics
|
Aug 08, 2023 | HOLD |
Strong Buy
+115.0% avg upside
15 analysts
|
— | +104.3% |
|
BTAI
Bioxcel Therapeutics
|
Jul 17, 2023 | HOLD |
Buy
+2634.1% avg upside
12 analysts
|
— | -88.1% |
|
BLCO
Bausch + Lomb Corporation
|
May 31, 2022 | BUY |
Buy
+21.0% avg upside
19 analysts
|
$24.00
48.35% Upside
|
+5.1% |
|
XCUR
Exicure
|
May 15, 2020 | BUY |
Buy
+5625.6% avg upside
4 analysts
|
$9.00
442.25% Upside
|
-38.9% |
|
AGIO
Agios Pharma
|
Jul 20, 2018 | BUY |
Buy
+50.0% avg upside
29 analysts
|
$123.00
206.90% Upside
|
-48.6% |
|
LITS
Lite Strategy
|
Jul 13, 2018 | BUY |
Strong Buy
+1019.4% avg upside
13 analysts
|
$12.00
1204.66% Upside
|
· |
|
CBIO
Crescent Biopharma
|
Dec 12, 2017 | BUY |
Strong Buy
+38.9% avg upside
17 analysts
|
$32.00
98.92% Upside
|
· |
|
TGTX
TG Therapeutics
|
Oct 18, 2017 | BUY |
Strong Buy
-31.8% avg upside
19 analysts
|
— | -29.8% |
|
OMER
Omeros
|
Aug 13, 2014 | BUY |
Buy
+106.0% avg upside
14 analysts
|
— | -3.4% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.